Lentiviral vectors are indispensable tools in cell and gene therapy (CGT) research, due to their ability to stably integrate genetic material into both dividing and non-dividing cells. Their versatility makes them particularly well-suited for delivering a wide range of payloads — from classical gene addition constructs to complex multi-cistronic CARs, CRISPR-Cas components and regulatory circuits that enable precise expression control.
As CGT advances toward more sophisticated platforms, including in vivo delivery, lentiviral vectors are playing an increasingly critical role. This webinar will focus on the latest innovations driving the application of lentiviral systems in CGT therapy, particularly in vivo CAR-T therapies. Industry experts will share advanced strategies in vector design, packaging optimization and producer cell line engineering that significantly improve viral yields, enhance gene delivery in hard-to-transduce cells and ensure consistent, high-quality functional titers.
Register for this webinar to gain insights into lentivirus innovations driving breakthroughs in in vivo CAR-T and gene delivery.
Speaker
Chuanxin Liu, PhD, Head of Viral Vector R&D, Life Science Group, GenScript Biotech Corporation
Dr. Chuanxin Liu received his PhD in Immunology from La Trobe University, Australia. He specializes in virology, viral vector development and cell engineering, with extensive experience in lentiviral and retroviral systems. His recent work focuses on optimizing vector design, improving yields and enhancing transduction efficiency for early-stage CGT applications, including CAR-T and in vivo gene delivery. Dr. Liu currently serves as the Head of Viral Vector R&D, leading efforts to advance research-grade viral vector platforms for innovation in cell and gene therapy.
Message PresenterWho Should Attend?
Attendees may include professionals focused on the following research areas and job functions:
Research Areas
- Gene therapy development
- Cell therapy
- Stable cell line generation
- Gene editing
- CRISPR screening, functional genomics
Job Titles
- Research Scientists
- CRISPR Researchers
- Director, Chief Technology Officer and Chief Scientific Officer
- Gene & cell therapy biotech & pharma R&D – those using lentiviral vectors for gene delivery, CAR-T or other cell therapies and seeking reliable lentiviral packaging services to accelerate preclinical projects
- Academic research – lab members working on gene editing (e.g., CRISPR), cell and gene therapy development (CAR-T, TCR-T, in vivo CAR-T), stable cell line generation or in vivo studies
What You Will Learn
Attendees will gain insight into:
- LVV applications in action: early-stage cell therapy development, target validation and next-gen in-vivo CAR-T delivery, supported by real-world examples
- High-titer lentivirus production: scalable solutions overcoming production challenges for complex constructs and hard-to-express payloads
- Streamlined CGT workflows: optimized LVV platforms, accelerating proof-of-concept studies and delivering high-titer lentivirus in just 5 business days
Xtalks Partner
GenScript
GenScript is the leading contract research organization in the world providing gene, peptide, protein, CRISPR, and antibody. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science research, translational biomedical research, and early stage pharmaceutical development. The company is recognized as having built a best-in-class capacity and capability for biological research services, encompassing gene synthesis, peptide synthesis, custom antibody and protein engineering, and in vitro and in vivo pharmacology – all with the goal to Make Research Easy.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account